EU pharma strategy could allow for shorter drug patents

A long-awaited proposal for the EU pharmaceutical strategy from the European Parliament doesn't directly reject the notion of changing the length of EU drug patents.

Photo: Jens Dresling

The EU pharmaceutical strategy moves ahead without any clear objections – particularly pertaining to drug patent rights – from the EU Committee on the Environment, Public Health and Food Safety (ENVI), one of the negotiators behind the proposed strategy, Linea Søgaard-Lindell, reports.

In the proposed strategy text – which will be put to vote on Monday and Tuesday – the Committee opens up for the possibility of looking into the pharmaceutical industry's "incentive structures." This wording could potentially allow the Commission to shorten the duration of drug patents in Europe, admits Søgaard-Lidell, who has negotiated on behalf of the liberal group Renew Europe.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs